Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG 80 Piotroski F-Score is 7 as of Jul. 29, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates WAR:RDG with a GF Score™ of 80/100 and a GF Value™ of zł6.37 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,330 Biotechnology companies, Read-Gene ranks better than 96.84% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Read-Gene has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Read-Gene's Piotroski F-Score or its related term are showing as below:
WAR:RDG'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 8
Current: 7
During the past 13 years, the highest Piotroski F-Score of Read-Gene was 8. The lowest was 4. And the median was 6.
Read-Gene (WAR:RDG) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Read-Gene Piotroski F-Score Related Terms
Read-Gene Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Read-Gene's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, RVMD: Piotroski F-Score Comparison
For the Biotechnology subindustry, Read-Gene's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Read-Gene's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Read-Gene's current Net Income (TTM) was 1.99.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Read-Gene's return on assets of this year was 0.16151035. Read-Gene's return on assets of last year was -0.0628374.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Read-Gene's current ratio of this year was 4.40884784. Read-Gene's current ratio of last year was 2.3385676.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Read-Gene's number of shares in issue this year was 11.79. Read-Gene's number of shares in issue last year was 11.79.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Read-Gene's gross margin of this year was 0.9423343. Read-Gene's gross margin of last year was 0.93144386.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Read-Gene's asset turnover of this year was 1.29127081. Read-Gene's asset turnover of last year was 1.04887353.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
0
+
1
+
0
+
1
+
1
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Read-Gene has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Read-Gene (WAR:RDG) has a Piotroski F-Score of 7 as of Jul. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Read-Gene and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Read-Gene's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Read-Gene ranks #42 out of 1330 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Read-Gene's Piotroski F-Score too high?
Read-Gene's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Read-Gene's value of 7 is 133.3% above this industry median. Based on the distribution chart, Read-Gene ranks #42 out of 1330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Read-Gene has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #42 out of 1330 companies for Piotroski F-Score. This places Read-Gene in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Read-Gene's value of 7 is 133.3% above this benchmark. Historically, Read-Gene's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Read-Gene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,330 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Read-Gene's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Read-Gene and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Read-Gene's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.37, compared to a current price of zł4.86 — trading 23.7% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 133.3% above the Biotechnology industry median of 3.00. Read-Gene's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Piotroski F-Score is 7 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł4.86 is trading 23.7% below its estimated GF Value™ of zł6.37.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
GF Value™: zł6.37 vs. price of zł4.86 (23.7% below fair value)
Industry Position: 133.3% above the Biotechnology median (#42 of 1330)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
80GF Score
Get the complete analysis for WAR:RDG
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
